PL2922850T3 - Związki i sposoby ich stosowania - Google Patents
Związki i sposoby ich stosowaniaInfo
- Publication number
- PL2922850T3 PL2922850T3 PL13857585T PL13857585T PL2922850T3 PL 2922850 T3 PL2922850 T3 PL 2922850T3 PL 13857585 T PL13857585 T PL 13857585T PL 13857585 T PL13857585 T PL 13857585T PL 2922850 T3 PL2922850 T3 PL 2922850T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/085023 WO2014079011A1 (en) | 2012-11-22 | 2012-11-22 | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| PCT/CN2013/000294 WO2014079136A1 (en) | 2012-11-22 | 2013-03-15 | Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof |
| EP13857585.7A EP2922850B1 (en) | 2012-11-22 | 2013-11-21 | Compounds and their methods of use |
| PCT/CN2013/001428 WO2014079150A1 (en) | 2012-11-22 | 2013-11-21 | Compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2922850T3 true PL2922850T3 (pl) | 2018-12-31 |
Family
ID=50775393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13857585T PL2922850T3 (pl) | 2012-11-22 | 2013-11-21 | Związki i sposoby ich stosowania |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10087172B2 (pl) |
| EP (2) | EP3456719A1 (pl) |
| JP (2) | JP6333277B2 (pl) |
| KR (1) | KR20150085079A (pl) |
| CN (2) | CN108727307A (pl) |
| AR (1) | AR093598A1 (pl) |
| AU (2) | AU2013347771B2 (pl) |
| BR (1) | BR112015011830A2 (pl) |
| CA (1) | CA2893510C (pl) |
| CL (1) | CL2015001392A1 (pl) |
| CR (1) | CR20150316A (pl) |
| CY (1) | CY1120581T1 (pl) |
| DK (1) | DK2922850T3 (pl) |
| EA (2) | EA201890754A1 (pl) |
| EC (1) | ECSP15026557A (pl) |
| ES (1) | ES2690390T3 (pl) |
| HR (1) | HRP20181628T1 (pl) |
| HU (1) | HUE040111T2 (pl) |
| IL (1) | IL238958B (pl) |
| LT (1) | LT2922850T (pl) |
| MX (1) | MX367389B (pl) |
| MY (1) | MY177344A (pl) |
| NZ (1) | NZ708382A (pl) |
| PE (1) | PE20151072A1 (pl) |
| PH (2) | PH12015501150B1 (pl) |
| PL (1) | PL2922850T3 (pl) |
| PT (1) | PT2922850T (pl) |
| RS (1) | RS57859B1 (pl) |
| SA (1) | SA515360469B1 (pl) |
| SG (2) | SG11201504049VA (pl) |
| SI (1) | SI2922850T1 (pl) |
| SM (1) | SMT201800504T1 (pl) |
| TR (1) | TR201812360T4 (pl) |
| TW (2) | TW201906825A (pl) |
| UA (1) | UA117360C2 (pl) |
| WO (3) | WO2014079011A1 (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| RS62447B1 (sr) | 2012-11-16 | 2021-11-30 | Calithera Biosciences Inc | Heterociklični inhibitori glutaminaze |
| EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CA2892817A1 (en) * | 2012-12-03 | 2014-06-12 | Calithera Biosciences Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| CN105960405B (zh) * | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| BR112016021620A2 (pt) | 2014-03-21 | 2018-07-10 | Agios Pharmaceuticals Inc | compostos e seus métodos de uso |
| CR20160497A (es) | 2014-04-30 | 2016-12-20 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| JP6619758B2 (ja) | 2014-07-03 | 2019-12-11 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 疾患を処置するためのｇｌｓ１阻害薬 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016014890A1 (en) * | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| WO2016054388A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
| EA035354B1 (ru) | 2015-04-06 | 2020-06-01 | Калитера Байосайенсиз, Инк. | Лечение рака легких ингибиторами глутаминазы |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| ES2794868T3 (es) * | 2015-06-30 | 2020-11-19 | Univ Texas | Inhibidores de GLS1 para el tratamiento de enfermedades |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3359150A4 (en) | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| CN106890184B (zh) * | 2015-12-18 | 2019-06-25 | 诺言医药科技(上海)有限公司 | 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用 |
| SG11201804664XA (en) | 2015-12-22 | 2018-07-30 | Univ Texas | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
| JP2019524852A (ja) | 2016-08-25 | 2019-09-05 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を用いる併用療法 |
| SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| EP3697764B1 (en) | 2017-10-18 | 2025-06-11 | Board Of Regents, The University Of Texas System | Gls-1 inhibitors for use in the treatment of cancer |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN113194752A (zh) | 2018-06-01 | 2021-07-30 | 康奈尔大学 | Pi3k相关疾病或病症的组合疗法 |
| US20210403479A1 (en) | 2018-11-08 | 2021-12-30 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
| WO2020191356A1 (en) * | 2019-03-21 | 2020-09-24 | Goncalves Marcus | Anti-fructose therapy for colorectal and small intestine cancers |
| CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
| CN112898200A (zh) * | 2021-01-20 | 2021-06-04 | 都创(上海)医药科技股份有限公司 | 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
| US4070400A (en) | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| SU1761672A1 (ru) * | 1990-05-22 | 1992-09-15 | Белгородский технологический институт строительных материалов им.И.А.Гришманова | Способ получени тонкодисперсного мела |
| EP0691962B1 (en) | 1993-03-29 | 2000-09-13 | Basf Aktiengesellschaft | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
| US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
| EP1087951B9 (en) | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| WO2001062206A2 (en) | 2000-02-22 | 2001-08-30 | Mount Sinai School Of Medicine Of New York University | N-cadherin modulated migration, invasion, and metastasis |
| US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| DE60200248T2 (de) | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Verfahren für Lösung-basierte Diagnose |
| WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
| US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| DE602006016085D1 (de) | 2005-03-16 | 2010-09-23 | Genentech Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| US8716472B2 (en) | 2006-10-16 | 2014-05-06 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
| CN101932605B (zh) | 2007-11-19 | 2014-06-11 | 健泰科生物技术公司 | 用于抑制肿瘤进展的组合物和方法 |
| US7951549B2 (en) | 2008-03-07 | 2011-05-31 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP3021120A1 (en) | 2009-02-20 | 2016-05-18 | Michael P. Lisanti | Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample |
| WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
| JP2012524280A (ja) | 2009-04-17 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー |
| WO2011143160A2 (en) * | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| ES2812457T3 (es) | 2010-06-23 | 2021-03-17 | Univ Louisville Res Found Inc | Uso de ácidos grasos en procedimientos para detectar cáncer |
| WO2012006506A1 (en) * | 2010-07-09 | 2012-01-12 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| WO2013138790A1 (en) | 2012-03-15 | 2013-09-19 | Research Foundation Of State University Of New York | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
| EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014138391A1 (en) | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
| CN105960405B (zh) | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| BR112016021620A2 (pt) | 2014-03-21 | 2018-07-10 | Agios Pharmaceuticals Inc | compostos e seus métodos de uso |
-
2012
- 2012-11-22 WO PCT/CN2012/085023 patent/WO2014079011A1/en not_active Ceased
-
2013
- 2013-03-15 WO PCT/CN2013/000294 patent/WO2014079136A1/en not_active Ceased
- 2013-11-21 MX MX2015006493A patent/MX367389B/es active IP Right Grant
- 2013-11-21 HR HRP20181628TT patent/HRP20181628T1/hr unknown
- 2013-11-21 SG SG11201504049VA patent/SG11201504049VA/en unknown
- 2013-11-21 MY MYPI2015001355A patent/MY177344A/en unknown
- 2013-11-21 PE PE2015000674A patent/PE20151072A1/es unknown
- 2013-11-21 ES ES13857585.7T patent/ES2690390T3/es active Active
- 2013-11-21 LT LTEP13857585.7T patent/LT2922850T/lt unknown
- 2013-11-21 US US14/646,634 patent/US10087172B2/en active Active
- 2013-11-21 PT PT13857585T patent/PT2922850T/pt unknown
- 2013-11-21 AU AU2013347771A patent/AU2013347771B2/en not_active Ceased
- 2013-11-21 EA EA201890754A patent/EA201890754A1/ru unknown
- 2013-11-21 NZ NZ708382A patent/NZ708382A/en unknown
- 2013-11-21 WO PCT/CN2013/001428 patent/WO2014079150A1/en not_active Ceased
- 2013-11-21 BR BR112015011830A patent/BR112015011830A2/pt not_active Application Discontinuation
- 2013-11-21 CN CN201810824418.2A patent/CN108727307A/zh active Pending
- 2013-11-21 SG SG10201609940RA patent/SG10201609940RA/en unknown
- 2013-11-21 HU HUE13857585A patent/HUE040111T2/hu unknown
- 2013-11-21 JP JP2015543242A patent/JP6333277B2/ja not_active Expired - Fee Related
- 2013-11-21 PL PL13857585T patent/PL2922850T3/pl unknown
- 2013-11-21 CN CN201380070365.5A patent/CN104936954B/zh not_active Expired - Fee Related
- 2013-11-21 EA EA201590987A patent/EA030646B1/ru not_active IP Right Cessation
- 2013-11-21 RS RS20181133A patent/RS57859B1/sr unknown
- 2013-11-21 CA CA2893510A patent/CA2893510C/en active Active
- 2013-11-21 UA UAA201506066A patent/UA117360C2/uk unknown
- 2013-11-21 TR TR2018/12360T patent/TR201812360T4/tr unknown
- 2013-11-21 SI SI201331140T patent/SI2922850T1/sl unknown
- 2013-11-21 EP EP18183580.2A patent/EP3456719A1/en not_active Withdrawn
- 2013-11-21 KR KR1020157016414A patent/KR20150085079A/ko not_active Ceased
- 2013-11-21 DK DK13857585.7T patent/DK2922850T3/en active
- 2013-11-21 EP EP13857585.7A patent/EP2922850B1/en active Active
- 2013-11-21 SM SM20180504T patent/SMT201800504T1/it unknown
- 2013-11-22 TW TW107111990A patent/TW201906825A/zh unknown
- 2013-11-22 TW TW102142566A patent/TWI629268B/zh not_active IP Right Cessation
- 2013-11-22 AR ARP130104322A patent/AR093598A1/es unknown
-
2015
- 2015-05-21 IL IL238958A patent/IL238958B/en not_active IP Right Cessation
- 2015-05-22 PH PH12015501150A patent/PH12015501150B1/en unknown
- 2015-05-22 CL CL2015001392A patent/CL2015001392A1/es unknown
- 2015-05-22 SA SA515360469A patent/SA515360469B1/ar unknown
- 2015-06-15 CR CR20150316A patent/CR20150316A/es unknown
- 2015-06-22 EC ECIEPI201526557A patent/ECSP15026557A/es unknown
-
2017
- 2017-11-24 PH PH12017502141A patent/PH12017502141A1/en unknown
-
2018
- 2018-04-24 JP JP2018082754A patent/JP2018150316A/ja active Pending
- 2018-04-30 AU AU2018202954A patent/AU2018202954A1/en not_active Abandoned
- 2018-08-17 CY CY20181100864T patent/CY1120581T1/el unknown
- 2018-08-21 US US16/107,220 patent/US10689375B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201609940RA (en) | Compounds and their methods of use | |
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| ZA201502503B (en) | Hppd variants and methods of use | |
| ZA201405248B (en) | Anesthetic compounds and related methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| EP2879676A4 (en) | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| ZA201408856B (en) | Heteroaryl compounds and methods of use thereof | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| AU2012900651A0 (en) | Compounds and methods of their use | |
| AU2012900650A0 (en) | Compounds and methods of their use | |
| GB201213726D0 (en) | Novel compounds and their use | |
| AU2012903090A0 (en) | Compounds and methods of their use - IV | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment |